TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06548139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natural full human monoclonal antibody CBB 1 injection 50.0µg/kg
Description: Active ingredient: natural full human monoclonal antibody CBB 1 containing 0.5 mg / ml per dose (2.5ml) Ingredients: 25 mM citrate buffer, 125 mM sodium chloride, 0.02% (w / v) polysorbate 20 and water for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natural full human monoclonal antibody CBB 1 injection 100.0µg/kg
Description: Active ingredient: natural full human monoclonal antibody CBB 1 containing 0.5 mg / ml per dose (2.5ml) Ingredients: 25 mM citrate buffer, 125 mM sodium chloride, 0.02% (w / v) polysorbate 20 and water for injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabies Human Immunoglobulin (HRIG)
Description: Active ingredient: Rabid human immunoglobulin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lyophilized rabies vaccine for human use (Vero cells)
Description: Active ingredient: inactivated rabies virus fixed poison

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lyophilized rabies vaccine for human use (Vero cells)
Description: Active ingredient: inactivated rabies virus fixed poison

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Lyophilized rabies vaccine for human use (Vero cells)
Description: Active ingredient: inactivated rabies virus fixed poison
Study: NCT05483829

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adhera® Fatigue for Long COVID program
Description: Adhera® for the Long COVID program, which includes an application and a smartwatch, supported by digital health solution based on emotional and behavioral change techniques. Patient Adaptative Self-Management Content (e.g. psycho-educational content, activities for mental wellbeing, personalized motivational messages), and the personalization is based on Adhera® Health Recommender System.~Wearable devices and the mobile app will be used to collect real-time data for 4 weeks to detect biometric and psychometric (patient-reported outcomes) information.
Study: NCT05865691

Intervention type: OTHER
Intervention: biomarker assay
Description: blood sample on the day of inclusion

Intervention type: OTHER
Intervention: biomarker assay
Description: blood sample on the day of inclusion

Intervention type: OTHER
Intervention: biomarker assay
Description: blood sample on the day of inclusion

Intervention type: OTHER
Intervention: biomarker assay
Description: blood sample on the day of inclusion
Study: NCT05968209

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lab4P
Description: Probiotic containing:~Lactobacillus acidophilus - CUL 60 Lactobacillus acidophilus - CUL 21 Bifidobacterium bifidum - CUL 20 Bifidobacterium animalis subsp. lactis - CUL34 Lactobacillus plantarum - CUL 66

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05357417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: utidelone
Description: 30mg/m2 (±10%), day 1-5 every 3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: utidelone
Description: 30mg/m2 (±10%), day 1-5 every 3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15mg/kg, day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15mg/kg, day 1
Study: NCT05561335

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hearing aid -novel program
Description: novel microphone configuration

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hearing aid - standard program
Description: standard microphone configuration
Study: NCT06115889

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smart Taiko Drumming
Description: Participants will play drumming with the developed Smart Taiko Drumming System for 30-45 minutes three times per week for 16 weeks, in addition to usual care.
Study: NCT04990817

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Average American Diet With SoFAS Replaced With Avocado
Description: Replacing energy from solid fats and added sugars (SoFAS) with Avocado as part of an average American diet

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Average American Diet
Description: Average American diet based on macronutrient analyses from the most recent Nutrition and Health Examination Survey.
Study: NCT06705595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tracheo-Spray
Description: Participants will receive 2 ml of 10% lidocaine delivered via a Tracheo-Spray device to the tracheal mucosa before anesthesia induction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Spray on DLT
Description: Before intubation, participants will receive 10% lidocaine spray applied to the distal surface and cuffs of the double-lumen tube (DLT).

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline (Placebo)
Description: Before intubation, participants will receive 1 ml of 0.9% saline applied to the distal surface and cuffs of the double-lumen tube (DLT).
Study: NCT06744907

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 10% Povidone-Iodine Arm
Description: A second application of surgical antisepsis with a topical povidone-iodine in the subdermal layer after making an incision.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Saline Arm
Description: An application of saline in the subdermal layer after making an incision.
Study: NCT06751381

Intervention type: DEVICE
Intervention: IVIM Imaging MRF Imaging
Description: IVIM imaging will be performed to evaluate microstructural and perfusion changes in the salivary glands of nasopharyngeal carcinoma patients undergoing radiotherapy. This technique quantifies diffusion and perfusion parameters, providing insights into early tissue damage.~MRF imaging will be used to quantify salivary gland tissue characteristics, including relaxation parameters (T1 and T2 mapping), to monitor radiotherapy-induced damage. The technique enables precise tissue characterization through multi-parametric MRI.
Study: NCT06750250

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient education
Description: The group A will be Education and Self-Management. Patient Education: Providing information on the benefits of physical activity, proper exercise techniques, and self-care strategies.~Self-Management Programs: Empowering women to take an active role in managing their health and fitness. Frequency: 3 session/ month, Intensity: Mild to moderate, Type: Walking Time: 30 to 45mints /sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobics
Description: Treadmill: A manual Treadmill intervention involves moderate-intensity aerobic exercise on a treadmill for 15 minute with the heart rate gradually reaching 75-85% of the maximum. Training frequency was not specified. It significantly reduced menstrual pain intensity 3 session per month. Stationary Bicycling: Start with gentle, low-intensity cycling and gradually increase as comfort allow the duration of exercise 10 mints per month. Running : The running is a low intensity effort of short to moderate duration 10 to 15 mints per mile
Study: NCT06742333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Bimekizumab 320mg given at weeks wk0, wk4, wk8 and wk12
Study: NCT05141799

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high intensity laser therapy
Description: Laser treatment is noninvasive and painless and can be easily administered in therapy units for a wide range of conditions. High-intensity laser therapy (HILT) has gained importance for the treatment of different kinds of sports injuries such as tendon injuries, contusions, and muscle spasms.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: high intensity laser therapy
Description: Laser treatment is noninvasive and painless and can be easily administered in therapy units for a wide range of conditions. High-intensity laser therapy (HILT) has gained importance for the treatment of different kinds of sports injuries such as tendon injuries, contusions, and muscle spasms.
Study: NCT06742333

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobetasol
Description: Once daily evening application of 0.05% of clobetasol ointment for up to 4 weeks
Study: NCT06765980

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: VV-14295
Description: VV-14295 will be administered as a single suprachoroidal injection.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: VV-14295
Description: VV-14295 will be administered as a single suprachoroidal injection.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: VV-14295
Description: VV-14295 will be administered as a single suprachoroidal injection.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: VV-14295
Description: VV-14295 will be administered as a single suprachoroidal injection.
Study: NCT06768788

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Face-to-face and web-based need-supportive intervention program based on the main tenets of SDT in the field of PE 1
Description: Intervention: need support, two-month face-to-face and web-based need-supportive intervention program for PE teachers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face-to-face and web-based need-supportive intervention program based on the main tenets of SDT in the field of PE 1
Description: Intervention: need support, two-month face-to-face and web-based need-supportive intervention program for PE teachers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face-to-face and web-based need-supportive intervention program based on the main tenets of SDT in the field of PE 2
Description: Intervention: autonomy or competence or relatedness support, one-month face-to-face and web-based need-supportive intervention program for PE teachers.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Face-to-face and web-based need-supportive intervention program based on the main tenets of SDT in the field of PE 2
Description: Intervention: autonomy or competence or relatedness support, one-month face-to-face and web-based need-supportive intervention program for PE teachers.
Study: NCT06773845

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TheraSphere
Description: The multicompartment MIRD model (a.k.a. partition model) based on diagnostic CT/MRI and 99mTc-MAA SPECT-CT will be used to plan a targeted dose of 700 Gy (± 50%) to the tumor. Given the high tumor burden, a scheduled second radioembolization within 120 days from the initial treatment will be permitted at the discretion of the operators provided the cumulative lung dose remains below 50 Gy. A scheduled second radioembolization may be considered when the largest tumor diameter exceeds 8 cm, or the estimated lung dose reaches 30 Gy while the tumor absorbed dose remains below the target dose of 700 Gy. The radioactive microsphere delivery device used will be glass-based (TheraSphere; Boston Scientific, MA, USA), in which Y90 is an integral constituent of the biocompatible glass matrix. Dosimetry planning will be made by personalized dosimetry software (Simplicit90y; Boston Scientific).
Study: NCT06771544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given PO
Study: NCT06771050

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Debridement and Implant Retention (DAIR)
Description: Intervention 1: DAIR- cleaning of infected joint including irrigation, debridement and exchange of modular components (those not fixed to bone) with implant retention.~Intervention 2: Single stage revision - cleaning of infected joint including irrigation, removal and placement of definitive new components which could be primary or revision components.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic Choice
Description: No intervention: Backbone antibiotic therapy only depends on the organism and is detailed in the protocol.~Intervention: Backbone antibiotic therapy plus rifampicin. Dosage 600-900mg per day orally for as long as oral antibiotic treatment continues, but not more than 12 weeks. Prescribed according to local recommended practices and dosed as per local therapeutic guidelines.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic duration Part A - Single stage revision
Description: Intervention Arm: Short course 6-week (42 +/- 7 days) antibiotic course - combined intravenous and oral with antibiotic choice according to organism and patient tolerability factors.~Intervention Arm: Long course 12- week (84 +/- 7 days) antibiotic course - combined intravenous and oral with antibiotic choice according to organism and patient tolerability factors.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic Duration Part B - Two stage revision
Description: Intervention Arm: Extended prophylaxis for 12 weeks after the 2nd stage revision surgery.~Intervention Arm: No extended antibiotic prophylaxis after the 2nd stage revision surgery.~Antibiotic choice by treating team with reference to the original causative organism(s), susceptibility and patient tolerability.
Study: NCT06772675

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: External Facilitation
Description: Designated external facilitators will conduct monthly meetings with local champions at each site. Designated facilitators will follow the developed facilitation guide, that includes content area to cover in each meeting, case scenarios as examples, and tips on how to communicate and support the internal facilitators. The goal is to enable problem-solving and support the local champion in implementing VRP with fidelity
Study: NCT06772285

Intervention type: OTHER
Intervention: Albert Health app
Description: Test an existing digital health app, called Albert Health, designed to support patients with a newly inserted feeding tube to use and manage their tube care, in a feasibility study.
Study: NCT06773728

Intervention type: DEVICE
Intervention: Record occlusal contacts
Description: Register using a digital device (t-scan) the occlusal contacts

Intervention type: DEVICE
Intervention: Tracking of jaw movement
Description: An optical jaw tracking system (Modjaw, Modjaw) is going to be implemented

Intervention type: DEVICE
Intervention: Tracking of jaw movement
Description: Jaw tracking will be performed using an optical jaw tracking system (Zebris, Zebris medical)
Study: NCT06770530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: 400 mg inravenous Fluconazole, single dose 200 ml

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline solution
Description: Intravenous saline solution, single dose 200 ml
Study: NCT06772636

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: music group
Description: In the music group, the music chosen by the participant will be played through a speaker by the nursing staff during outpatient hysteroscopy. Music will be played through a speaker instead of headphones in order to maintain good communication and interaction between the participant and the doctor.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: non music group
Description: Participants in the non-music group will undergo hysterosalpingography in the same setting and standard procedure without listening to any music.
Study: NCT06771089

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy and bandaging
Description: The MTG group received an intervention based on anterior-posterior mobilizations of the talus and fibula and taping, both based on Mulligan® techniques Individually, participants received Grade IV passive mobilizations lasting approximately 30 seconds, totalling 12 active mobilizations performed by the participant. Furthermore, a tape was applied, placed on the anterior part of the talus with a posterior and caudal direction, with its ends anchored near the heel. Due to its placement, this taping maintained a sustained posterior force on the talus throughout the training session. This intervention was conducted on the affected limb(s) with DF deficits.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise
Description: Therapeutic exercise protocol lasting approximately 5-10 minutes, performed before regular training sessions. It included 2 exercises, each performed in 3 sets of 10 repetitions with 1-minute rest intervals.~Exercise 1: Weighted DF in a kneeling position. From this position, ankle DF is performed with the front leg, on which the weight of the arms and the torso is placed to force the movement.~Exercise 2: Ankle lunge with band resistance at the ankle. The player performs ankle DF with a medium-resistance green Theraband® providing a posterior force vector on the talus.~This intervention was applied to the affected limb(s) with ankle DF limitations and was supervised by a physiotherapist. It was performed before training session at each club's facilities.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No specific treatment
Description: The Control group received no specific treatment; they only participated in the current training sessions.
Study: NCT06773312

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BC001+Sintilimab+XELOX
Description: patients will be given : BC001 8mg/kg, 12mg/kg or 16mg/kg intravenously once every three weeks; Sintilimab 3mg/kg（body weight\<60kg）or 200mg（body weight≥60kg）intravenously once every three weeks; Oxaliplatin 130mg/m2 intravenously once every three weeks; Capecitabine 1000mg/m2 orally once daily in the first two weeks of each three-week treatment cycle.
Study: NCT06772662

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tubing Direction
Description: We are studying the procedure of placing the Cryotherapy Tubing in two different directions: up vs down

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tubing Direction
Description: We are studying the procedure of placing the Cryotherapy Tubing in two different directions: up vs down
Study: NCT06770296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib low dose group
Description: Pyrotinib: 320mg, peros(po),once a day(qd) ,every 3 weeks(q3w) Trastuzumab: 8mg/Kg in the first cycle, 6mg/Kg in the subsequent cycle, intravenous(iv), every 3 weeks(q3w) Docetaxel: 75mg/m2，intravenous(iv), every 3 weeks(q3w)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyrotinib normal dose group
Description: Pyrotinib: 400mg, peros(po),once a day(qd) ,every 3 weeks(q3w) Trastuzumab: 8mg/Kg in the first cycle, 6mg/Kg in the subsequent cycle, intravenous(iv), every 3 weeks(q3w) Docetaxel: 75mg/m2，intravenous(iv), every 3 weeks(q3w)
Study: NCT06771024

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Exercise
Description: The intervention include a personalized physical exercise program based on aerobic and strength training, with prior warm-up and post cool-down exercises. International/national exercise prescription guidelines will be applied for each clinical condition (cardio/cerebrovascular disease/risk, diabetes mellitus and osteoarthritis).
Study: NCT06771596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab Injection
Description: Nimotuzumab is a highly humanized monoclonal antibody of IgG1 type, with a humanization rate of 95%. It is highly specific, has a long half - life, and shows high selectivity and a high degree of humanization. It can specifically block the epidermal growth factor receptor (EGFR) signaling pathway and mediate immune effects such as antibody - dependent cell - mediated cytotoxicity (ADCC) and complement - dependent cytotoxicity (CDC). It also promotes the endocytosis and degradation of EGFR, thereby inhibiting the proliferation of tumor cells and promoting the apoptosis of tumor cells, reversing the malignant biological behavior of tumor cells at the molecular level.
Study: NCT06771492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Antibiotic treatment (amoxicillin) with a dosage of 1000 mg (3 times a day) for a period of 100 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with a dose of 1000 mg (3 times a day) for a period of 100 days
Study: NCT06770738

Intervention type: OTHER
Intervention: There is no intervention in this study.
Description: This study is planned as a retrospective cross sectional cohort study. Only the information of the patients will be used.
Study: NCT06773871

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Weekly supervised exercise for 12 weeks followed by 12 weeks of non-supervised exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Remain usual activity level
Study: NCT06771999

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational intervention by a clinical pharmacist
Description: All participants will respond to two questionnaires, both validated in Romanian and some demographic information. One is the rPATD questionnaire that investigate attitudes towards deprescribing of medication and the other one is the HLS-EU-Q16 that investigates medical literacy of participants. After completion, the clinical pharmacist will give a brochure and a video about the process of deprescribing, information about the efficacy and the adverse reactions of medicines and the role of pacient in treatment decision. When participants come to another cancer treatment (after 14 , 21 or 28 days), the rPATD will be completed again.
Study: NCT06148506

Intervention type: OTHER
Intervention: Ribociclib
Description: There is no treatment allocation. Participants with HR+HER2- aBC that initiated treatment with ribociclib+ET by prescription within the study enrollment timeline will be recruited.

Intervention type: OTHER
Intervention: Combination chemotherapy
Description: There is no treatment allocation. Participants with HR+HER2- aBC that initiated treatment with CT by prescription within the study enrollment timeline will be recruited.
Study: NCT06505759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromelain gel
Description: bromelain gel is prepared from bromelain capsules in laboratory

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chlorhexidine gel
Description: chlorhexidine gel is prepared from mouth wash

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SRP
Description: Scaling and root planing was done with ultra sonic and hand scaling
Study: NCT04294043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium nitrate
Description: Study subjects will receive an infusion of gallium nitrate.
Study: NCT06415773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTD1801
Description: HTD1801 1000 mg BID administered orally BID as four capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Dapagliflozin 10 mg tablet administered orally QD